Latest filing published 15 Aug 2022 for Kiromic Biopharma, Inc..
Insider track record
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
No signal scores available.
Scott Dahlbeck: trading record in brief
Scott Dahlbeck, listed as senior executive, appears in our data through filings on Kiromic Biopharma, Inc. shares, published by SEC (Form 4). We count 2 filings; the first trade dates from 23 May 2022 and the latest from 11 August 2022.
No open-market purchase or sale appears among the filings, only grants, plan transactions and other operations. Grants and option exercises follow pay plans set in advance, so they reveal less about an insider's own view than a purchase made with personal money.
The latest filing, published on 15 August 2022, reports a share grant in Kiromic Biopharma, Inc. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Companies and markets linked to Scott Dahlbeck
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
- 50,000 shares0Common StockSEC:0001104659-22-091245:0
- 17,240 sharesCommon StockSEC:0001104659-22-064646:0
2 of 2 declarations